Vor Biopharma (NASDAQ:VOR) Now Covered by Analysts at William Blair

Key Points

• William Blair initiated coverage of Vor Biopharma with an “outperform” rating. The stock has a consensus “Moderate Buy” rating and an average analyst price target of $38.00.
• Vor Biopharma shares opened at $19.03, with a 12-month trading range of $6.50 to $30.38. The company’s latest quarterly loss of $0.80 per share missed the consensus estimate of $0.69.
• Institutional investors and hedge funds own 97.29% of Vor Biopharma, while the clinical-stage biotechnology company continues developing engineered stem-cell and targeted immunotherapy treatments for blood cancers.

Equities research analysts at William Blair began coverage on shares of Vor Biopharma (NASDAQ:VOR - Get Free Report) in a research report issued on Wednesday, Briefing.com reports. The firm set an "outperform" rating on the stock.

A number of other research firms have also recently commented on VOR. Citigroup upgraded Vor Biopharma to a "strong-buy" rating in a report on Thursday, October 15th. Wall Street Zen raised Vor Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Wedbush raised their target price on Vor Biopharma from $18.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings upgraded Vor Biopharma from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday, September 14th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Vor Biopharma presently has a consensus rating of "Moderate Buy" and an average price target of $38.00.

Vor Biopharma Stock Up 5.5%

Shares of VOR stock opened at $19.03 on Wednesday. The firm's 50-day moving average is $21.38 and its two-hundred day moving average is $18.41. Vor Biopharma has a 12 month low of $6.50 and a 12 month high of $30.38.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). As a group, equities analysts predict that Vor Biopharma will post -2.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors have recently modified their holdings of the company. Cannon Global Investment Management LLC acquired a new position in Vor Biopharma during the 1st quarter worth about $209,000. Sei Investments Co. acquired a new position in Vor Biopharma in the 1st quarter valued at about $245,000. Independent Financial Group LLC acquired a new position in Vor Biopharma in the 1st quarter valued at about $249,000. Wellington Management Group LLP acquired a new position in Vor Biopharma in the 2nd quarter valued at about $499,000. Finally, Irenic Capital Management LP purchased a new stake in Vor Biopharma during the first quarter worth about $583,000. 97.29% of the stock is owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company's approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor's technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.